AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
From recent TIGIT failures to high-potential targets like VEGF, BioSpace explores what’s on the horizon in immuno-oncology. May 19, 2025· 2 min read· Heather McKenzie Radiopharmaceuticals Radiopharma Powerhouses Push Frontiers With New Indications, Innovation At the intersection of radiation...
Servier is a global pharmaceutical company focused on therapeutic progress to serve patient needs across various medical domains including cardiology and oncology. The company offers a range of targeted therapies and generic drugs aimed at treating cardiovascular diseases, cancers, and immuno-inflammatory ...
Finally, AstraZeneca is doing a lot of research on ADCs to deliver even better therapeutic outcomes to patients through ADC and immuno-oncology combinations, focusing on that ADCs play a crucial role in killing cancer cells and can enhance the response of immuno-oncology drugs. Q: What does As...
PE: Are there any other promising oncology agents in AstraZeneca’s pipeline that you wish to highlight? Doti: So, we are dedicating today into two different types of drugs to attack cancer: the ones that attack cancer directly, by targeting a mutation like EGFR mutations, like directing...
Analystspredictthat Astrazeneca’s PD-L1 drug for lung cancer holds a blockbuster potential. Moreover, AZN’s tremelimumab will only be second to market behind BMY’s Yervoy for immuno-oncology drugs that target the CTLA-4 (cytotoxic T-lymphocyte-associated protein 4). ...
Centers for Disease Control and Prevention. (n.d.). Covid-19 vaccines for people who are moderately or severely immunocompromised. Centers for Disease Control and Prevention. Retrieved November 10, 2022, fromhttps://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/im...
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. ...
Now, Seres has cleared AstraZeneca to test SER-401 in combination with other cancer treatments. Through these tests, AstraZeneca could gain an edge on the immuno-oncology leaders by rendering more people responsive to its drugs. “Despite progress in the field of immunotherapy, we are only at...
“The data presented at ASCO reinforce the importance MEDI4736 plays in our immuno-oncology portfolio, and more broadly, the potential role it has to help in transforming cancer therapy, alone and in combination with other treatments,” said Edward Bradley, senior vice president, R&D, at AZ’s...